What is Bortezomib-cyclophosphamide-dexamethasone (VCd or CyBorD)?

Category: Prescription Drugs

false

See also: Bortezomib Cyclophosphamide

Bortezomib-cyclophosphamide-dexamethasone, also known as VCd or CyBorD, is a regimen that may be used for the treatment of multiple myeloma. It contains the anticancer agents bortezomib and cyclophosphamide along with dexamethasone, a corticosteroid.

Side effects

Side effects as an overall problem

Side effects as an overall problem
Severity Evaluations Percentage
Severe 9
Moderate 16
Mild 9
None 5

Commonly reported side effects and conditions associated with Bortezomib-cyclophosphamide-dexamethasone (VCd or CyBorD)

Side effect Patients Percentage
Peripheral neuropathy 6
Fatigue 5
Constant tiredness 2
Numbness 2
Tiredness 2
Bone pain 1

Show all 24 reported side effects

Why patients stopped taking Bortezomib-cyclophosphamide-dexamethasone (VCd or CyBorD)

Multiple reasons could be selected

Reason Patients Percentage
Course of treatment ended 16
Did not seem to work 3
Doctor's advice 3
Side effects too severe 3
See all 22 patients who've stopped taking Bortezomib-cyclophosphamide-dexamethasone (VCd or CyBorD)

Duration

Currently taking Bortezomib-cyclophosphamide-dexamethasone (VCd or CyBorD)

Duration Patients Percentage
5 - 10 years 1

Stopped taking Bortezomib-cyclophosphamide-dexamethasone (VCd or CyBorD)

Duration Patients Percentage
Less than 1 month 3
1 - 6 months 11
6 months - 1 year 6
1 - 2 years 2
Adherence
Adherence Evaluations Percentage
Always 31
Usually 6
Sometimes 0
Never taken as prescribed 2
Burden
Burden Evaluations Percentage
Very hard to take 2
Somewhat hard to take 10
A little hard to take 12
Not at all hard to take 15
Cost per month
Cost per month Evaluations Percentage
$200+ 12
$100-199 1
$50-99 0
$25-49 3
< $25 6
Not specified 17

What people switch to and from

Patients started taking Bortezomib-cyclophosphamide-dexamethasone (VCd or CyBorD) after stopping:

Treatment Patients Percentage
Bortezomib (Velcade) 1
Lenalidomide (Revlimid) 1

Patients stopped taking Bortezomib-cyclophosphamide-dexamethasone (VCd or CyBorD) and switched to:

Treatment Patients Percentage
Lenalidomide-dexamethasone (Rd) 5
Bortezomib (Velcade) 2
Bortezomib-lenalidomide-dexamethasone (VRd) 1
Carfilzomib-lenalidomide-dexamethasone 1
Last updated:

1 patient evaluation for Bortezomib-cyclophosphamide-dexamethasone (VCd or CyBorD)

Sep 3, 2015 (Started May 30, 2015)

  • Effectiveness
    Major (for multiple myeloma)
  • Side effects
    Moderate (peripheral neuropathy)
  • Adherence
    Always
  • Burden
    Somewhat hard to take
Dosage: Weekly

Jun 4, 2015 (Started May 30, 2015)

  • Effectiveness
    Major (for multiple myeloma)
  • Side effects
    Moderate (peripheral neuropathy)
  • Adherence
    Always
  • Burden
    A little hard to take
Dosage: Weekly

  • 0 helpful marks
Last updated:
Showing 1 of 1 patient evaluation for Bortezomib-cyclophosphamide-dexamethasone (VCd or CyBorD)